It remains an investigational compound under development by Eli Lilly and Company, currently progressing through Phase 3 clinical trials
As GLP-1RAs appear to exert their cardiovascular benefit by mechanisms different from those of both pioglitazone and SGLT2 inhibitors, there would also seem to be a place for a randomised controlled trial comparing a GLP-1RA plus pioglitazone or a GLP-1RA plus SGLT2 inhibitor compared to each monotherapy alone to establish the extent to which extra benefit is accrued with dual or even triple therapy
Most people with diabetes taking GLP-1 medications see meaningful A1C reductions
Our online booking system is easy to navigate and open 24/7
Bulk-forming laxatives are generally safer for long-term use compared to stimulant laxatives, which can be harsher on the digestive system
In the first study, the authors did not find any significant difference in biochemical hyperandrogenism in both intra and inter-groups, despite the significant improvement in anthropometric parameters in the group treated with liraglutide [57]
